

Serum levels of sirtuin 6 are associated with severe community acquired pneumonia in children: an observational study

Los niveles séricos de sirtuin 6 se asocian con neumonía adquirida en la comunidad grave en niños: un estudio observacional

Yunjing Song^{*1}, Junmei Yang¹, Hongqi Sun¹, and Xin Mu²

¹Department of Laboratory Medicine, Henan Children's Hospital, Children's Hospital of Zhengzhou University, Zhengzhou; ²Department of Neonatal Surgery, Henan Children's Hospital, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou. Henan, China

Abstract

Objective: The objective of this study was to investigate the role of sirtuin 6 (SIRT6) in severe community acquired pneumonia (CAP) in child patients. **Methods:** This prospective observational research enrolled a total of 75 severe child CAP patients who went to our hospital during April 2016 to December 2020, and 75 mild/moderate CAP child patients were included as control. SIRT6 and inflammatory factors C-reactive protein (CRP), interleukin (IL)-6, and procalcitonin (PCT) were tested by the enzyme linked immunosorbent assay (ELISA). Demographic data including age, sex, as well as clinical symptoms, duration of ICU stay, duration of mechanical ventilation were collected. The routine blood test was conducted for all patients and WBC amount and neutrophil ratio were recorded. The pediatric critical illness score (PCIS) and 1-month mortality were collected. **Results:** Levels of SIRT6 were remarkably lower in severe CAP patients or deceased patients compared with mild/moderate or survival patients, respectively. Levels of CRP, PCT, and interleukin-6 (IL-6) were markedly higher in severe patients than mild/moderate patients. However, only levels of CRP were significantly higher in deceased CAP patients and serum levels of SIRT6 were negatively correlated with serum levels of CRP, PCT, and IL-6. The higher levels of CRP, PCT and IL-6, as well as higher mortality rate and lower levels of PCIS were found in patients with lower SIRT6 compared with patients with higher SIRT6. SIRT6 had the potential for diagnosis of severe CAP and patients with lower SIRT6 showed shorter 1-month survival. Further, logistic regression showed that only age and CRP were independent risk factors for 1-month mortality of CAP child patients. **Conclusion:** Down-regulated SIRT6 in severe CAP child patients predicted higher expression of inflammatory factors, severer clinical outcomes and poor prognosis.

Keywords: SIRT6. Community acquired pneumonia. Children. Prognosis. Observational study.

Resumen

Objetivo: Investigar el papel de sirtuin 6 (SIRT6) en la neumonía adquirida en la comunidad (NAC) grave en pacientes infantiles. **Métodos:** Esta investigación observacional prospectiva inscribió a un total de 459 pacientes con NAC infantil grave que acudieron a nuestro hospital entre abril de 2016 y diciembre de 2020, y se incluyeron como control 459 pacientes con NAC infantil leve/moderada. **Resultados:** Los niveles de SIRT6 fueron notablemente más bajos en pacientes con NAC grave o pacientes fallecidos en comparación con los pacientes leves/moderados o con supervivencia, respectivamente. Todos los niveles de PCR, PCT e Interleukin-6 (IL-6) fueron significativamente más altos en pacientes con CAP fallecidos y los niveles séricos de SIRT6 se correlacionaron negativamente con los niveles séricos de CRP, PCT e IL-6. Los niveles más altos de PRISM, CRP, PCT e IL-6, así como una mayor tasa de mortalidad y niveles más bajos de PCIS se encontraron en pacientes con menor SIRT6 en comparación con los padres con mayor SIRT6. SIRT6 tenía potencial para el diagnóstico de NAC grave.

*Correspondence:

Yunjing Song

E-mail: yjing_s4600@126.com

Date of reception: 26-10-2021

Date of acceptance: 07-01-2022

DOI: 10.24875/CIRUE.M22000551

Cir Cir (Eng). 2022;90(5):622-627

Contents available at PubMed

www.cirugiaycirujanos.com

2444-0507/© 2022 Academia Mexicana de Cirugía. Published by Permanyer. This is an open access article under the terms of the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Conclusión: La *SIRT6* regulada a la baja en pacientes infantiles con NAC grave predijo una mayor expresión de factores inflamatorios, resultados clínicos más graves y mal pronóstico.

Palabras clave: *SIRT6*. Neumonía adquirida en la comunidad. Niños. Pronóstico. Estudio observacional.

Introduction

Community acquired pneumonia (CAP) is a common respiratory disease accounting for more than 3 million deaths every year worldwide¹⁻³. In children, pneumonia is also a leading cause of morbidity and mortality worldwide, with an estimated of 120 million new cases every year and the mortality rate in severe patients is about 8.7%, especially for young infants^{4,5}. Due to the high mortality for severe CAP in children, the early diagnosis and treatment are very important for child patients⁶.

Sirtuin 6 (*SIRT6*) is a member in sirtuin family, which shows multiple bioactivities in many diseases, such as diabetes⁷, cancer⁸, and cardiovascular diseases⁹. Besides, *SIRT6* was also found to be associated with inflammation response. It was found the deficiency of *SIRT6* might be related to activated inflammation¹⁰. However, up to now, no study reported the clinical role of *SIRT6* in CAP patients.

In the present study, we aimed to investigate the role of *SIRT6* in severe CAP child patients, especially for its relationship with clinical outcomes and prognosis. This study might provide clinical evidence for *SIRT6* in CAP.

Materials and Methods

This cross-sectional research enrolled a total of 75 severe child CAP patients who went to our hospital during January 2018 to December 2020. All patients who met the following inclusion criteria during the study period were consecutively enrolled. The diagnosis of child CAP and severe CAP was according to the criteria of Chinese Medical Association (2013 version)¹¹. Briefly, the diagnosis criteria for CAP were: (1) patients with cough, expectoration, or aggravation of the original respiratory symptoms, purulent sputum, with or without chest pain; (2) fever; (3) signs of lung consolidation and/or auscultation of wet rales; (4) $WBC > 10 \times 10^9/L$ or $< 4.0 \times 10^9/L$, with or without left shift of neutrophils' nucleus; and (5) imaging examination showing patchy or patchy infiltration shadow or interstitial changes, with or without pleural effusion. Patients who were with any one of (1)~(4) and (5) were diagnosed as CAP. The diagnosis criteria of severe CAP were: (1) patients with temperature $\geq 38.5^\circ C$; (2) patients with respiratory rate $\geq 70/min$ for

0~3 years old child or respiratory rate $\geq 50/min$ for 4~14 years old child; (3) patients with inspiratory depression of chest wall; (4) patients with nasal fan, cyanosis, intermittent apnea, and breathing moan; (5) patients with dehydration sign; and (6) patients with severe complications including heart failure, respiratory failure, shock, microcirculation disturbance, toxic encephalopathy, sepsis, toxic intestinal paralysis (or) empyema, and pneumothorax. Patients with (1) and (2) and any of 3~6) were diagnosed as severe CAP. Other patients were defined as mild-moderate CAP. The following patients were excluded: (1) patients had taken antibiotics, antiviral drugs, or anti-inflammatory drugs within 3 months before the study; (2) patients with chronic inflammatory diseases such as asthma; and (3) patients with congenital diseases such as congenital heart disease and congenital hypothyroidism. Besides, this study also included 75 mild/moderate CAP child patients as control. Written informed consent was obtained from all the parents of the patients. The present study was approved by the Ethic Committee of Henan Children's Hospital, Children's Hospital of Zhengzhou University.

Measurement of serum *SIRT6* and inflammatory factors

Briefly, 5 mL peripheral venous blood were collected in EDTA tubes from all child within 24 h after admission. After centrifugation at 1500 g for 20 min, serum levels of *SIRT6*, interleukin (IL)-6, and procalcitonin (PCT) were tested by the enzyme linked immunosorbent assay (ELISA) using commercial kits (*SIRT6* cat no. MBS2705672, MYBio Source; interleukin-6 (IL-6) cat no. EK0410, BOSTERBio; PCT cat no. ab221828, Abcam). The serum levels of C reactive protein (CRP) were detected using an automatic biochemical analyzer (Hitachi 7600, Hitachi Corporation, Japan).

Data collection

Demographic data including age, sex, as well as clinical symptoms, duration of ICU stay, and duration of mechanical ventilation were collected. The routine blood test was conducted for all patients and WBC amount and neutrophil ratio were recorded.

For 1-month survival analysis, the pediatric critical illness score (PCIS) was collected. All course death for patients was considered for 1-month mortality and the mortality time was defined from the admission time to the death.

Statistical analysis

The distribution of the data was analyzed by Kolmogorov–Smirnov method. Normally distributed data were expressed by mean $\pm$ SD. Chi-square test was used to compare the rates. Comparison between two groups was analyzed by Student t-test. Pearman's analysis was conducted for correlation analysis. Kaplan–Meier (K-M) curve was performed for survival analysis. The receiver operating characteristic (ROC) curve was used for diagnostic analysis. Logistic regression analysis was conducted for 1-month mortality using binary regression analysis by a step back method. $p < 0.05$ was considered as statistically different. All calculations were made using SPSS 21.0 (SPSS Inc., Chicago, USA).

Results

Basic characteristics in all child patients

A total of 75 severe CAP child patients, as well as 75 mild/moderate CAP child patients were included in this study. As shown in table 1, severe CAP patients showed markedly higher ratios of fever, cough, shortness of breath, dyspnea, nasal fan/cyanosis, and severe complications ($p < 0.05$). Besides, the levels of CRP, PCT, IL-6, and WBC were all significantly higher, while levels of PCIS were remarkably lower in severe CAP patients ($p < 0.05$). Besides, the 1-month mortality rate was also significantly higher in severe patients ($p < 0.05$). No other significant difference was found.

Serum levels of SIRT6 were decreased in severe and deceased child CAP patients and were correlated with inflammatory factors

Then, the serum levels of SIRT6 were measured in different CAP patients. It was found that levels of SIRT6 were remarkably lower in severe CAP patients or deceased patients compared with mild/moderate or survival patients, respectively ($p < 0.05$) (Fig. 1). The inflammatory factors of CRP, PCT, and IL-6 were also measured. Results showed that only levels of CRP were

Table 1. Characteristics of all patients

Variable	Mild/moderate, (n = 75)	Severe CAP patients (n = 75)	p*
Mean age, years	5.17 $\pm$ 3.85	4.56 $\pm$ 3.29	0.297
Age range, n (%)			
0~4	36 (48.0)	39 (52.0)	0.572
5~14	39 (52.0)	36 (48.0)	
Sex, male: female	42: 33	47: 28	0.337
Symptoms, n (%)			
Fever	43 (57.33)	75 (100.00)	< 0.001
Cough	62 (82.67)	69 (92.00)	0.047
Sputum	59 (78.67)	64 (85.33)	0.220
Shortness of breath	23 (30.67)	50 (66.67)	< 0.001
Dyspnea	5 (6.67)	21 (28.00)	< 0.001
Nasal fan/cyanosis	2 (2.67)	20 (26.67)	< 0.001
Severe complications	0 (0.00)	11 (14.67)	< 0.001
PCIS	85.54 $\pm$ 5.90	75.34 $\pm$ 6.39	< 0.001
CRP, mg/L	26.48 $\pm$ 14.67	68.00 $\pm$ 29.59	< 0.001
PCT, μ g/mL	50.67 $\pm$ 23.70	122.99 $\pm$ 58.32	< 0.001
IL-6, pg/mL	85.93 $\pm$ 38.29	210.62 $\pm$ 93.15	< 0.001
WBC, 10^9 /mL	17.58 $\pm$ 4.55	22.31 $\pm$ 5.48	< 0.001
Neutrophil ratio (%)	58.51 $\pm$ 7.30	72.40 $\pm$ 8.91	< 0.001
1-month mortality (%)	2 (2.67)	12 (16.00)	0.001

*Comparison between severe and mild/moderate patients. Chi-square test was used to compare the rates. Comparison between two groups was analyzed by Student t-test.

CAP: community acquired pneumonia; PCIS: pediatric critical illness score; CRP: c-reactive protein; PCT: procalcitonin; IL-6: interleukin-6; WBC: white blood cells.

significantly higher in deceased CAP patients ($p < 0.05$). Further, Pearson's analysis showed that serum levels of SIRT6 were negatively correlated with serum levels of CRP, PCT, and IL-6 (all $p < 0.05$) (Table 2).

Serum levels of SIRT6 were associated with clinical outcomes of severe child CAP patients

To further reveal the role of SIRT6 in severe CAP patients, patients were divided into high SIRT6 group and low SIRT6 group according to the mean serum level of SIRT6 (9.32 ng/mL). As shown in table 3, the higher levels of CRP, PCT and IL-6, as well as higher mortality rate and lower levels of PCIS, as well as younger age were found in patients with lower SIRT6 compared with patients with higher SIRT6 ($p < 0.05$). Besides, higher percentage of patients with fever, shortness of breath, nasal fan/cyanosis, and severe complications were also observed in patients with lower SIRT6 ($p < 0.05$).




Figure 1. A: serum levels of SIRT6 in severe/mild-moderate and deceased/survival child CAP patients. **B:** serum levels of CRP, PCT and IL-6 in deceased/survival child CAP patients. *** $p < 0.001$, ** $p < 0.01$. SIRT6: sirtuin 6; CAP: community acquired pneumonia; CRP: c-reactive protein; PCT: procalcitonin; IL-6: interleukin-6.

Table 2. Pearson's correlation for SIRT6 and inflammatory factors

	SIRT6	CRP	PCT	IL-6
SIRT6				
Pearson's correlation	-	-0.381	-0.319	-0.388
p value	-	< 0.001	< 0.001	< 0.001
CRP				
Pearson's correlation	-0.381	-	0.454	0.507
p value	< 0.001	-	< 0.001	< 0.001
PCT				
Pearson's correlation	-0.319	0.454	-	0.489
p value	< 0.001	< 0.001	-	< 0.001
IL-6				
Pearson's correlation	-0.388	0.507	0.489	-
p value	< 0.001	< 0.001	< 0.001	-

SIRT6: sirtuin 6; CRP: c-reactive protein; PCT: procalcitonin; IL-6: interleukin-6.

No other significant difference was observed. These results indicated that lower levels of SIRT6 might be associated with higher expression of inflammatory factors and poor prognosis in severe CAP child patients.

Diagnostic value of SIRT6 for severe child CAP and its association with 1-month mortality

The diagnostic value of SIRT6 for severe child CAP was then determined using ROC curve. It was found that

SIRT6 had the potential for diagnosis of severe CAP in child patients with cutoff value 8.68 ng/mL, AUC0.863 (95% CI = 0.808-0.919), sensitivity 77.3%, and specificity 70.7% (Fig. 2). The K-M curve showed that patients with higher SIRT6 had significantly longer 1-month survival compared with patients with lower SIRT6 ($p < 0.05$) (Fig. 3). However, further logistic regression showed that only age and CRP were independent risk factors for 1-month mortality of severe CAP child patients (Table 4).

Discussion

Severe pneumonia is one of the main causes for death of children, especially for children under 5 years with higher mortality rate. Thus, the early diagnosis is of great significance for its treatment. In the present study, we demonstrated the role of a new inflammation-related factor, SIRT6, in severe CAP child patients. We found that SIRT6 is down-regulated in severe CAP patients, and lower SIRT6 expression was associated with the patients' severity and poor prognosis.

It is well-known that inflammation is a key factor for CAP development. CAP can activate inflammation response and enhance the release of cytokines^{12,13}. Inflammatory factors such as CRP, PCT, and IL-6 are all found to be associated with clinical severity scores and can predict treatment failure, guide acute in-hospital or

Table 3. Comparison of clinical outcomes between CAP child patients with high/low SIRT6 expression

Variable	High SIRT6, (n = 73)	Low SIRT6 (n = 77)	p*
Mean age, years	5.58 ± 3.93	4.18 ± 3.09	0.016
Age range, n (%)			
0~4	31 (42.47)	44 (57.14)	0.038
5~14	42 (57.53)	33 (42.86)	
Sex, male: female	40: 33	49: 28	0.203
Symptoms, n (%)			
Fever	50 (68.49)	68 (88.31)	0.001
Cough	66 (90.41)	65 (84.41)	0.201
Sputum	61 (83.56)	62 (80.51)	0.575
Shortness of breath	25 (34.25)	48 (62.34)	< 0.001
Dyspnea	11 (15.07)	15 (19.48)	0.409
Nasal fan/cyanosis	6 (8.22)	16 (20.78)	0.012
Severe complications	2 (2.74)	9 (11.69)	0.014
PCIS	83.20 ± 7.75	77.83 ± 7.33	< 0.001
CRP, mg/L	37.02 ± 25.88	56.93 ± 32.90	< 0.001
PCT, µg/mL	71.30 ± 48.02	101.56 ± 61.67	0.001
IL-6, pg/mL	120.01 ± 87.74	175.07 ± 93.59	< 0.001
WBC, 10 ⁹ /mL	19.03 ± 5.17	20.82 ± 5.79	0.049
Neutrophil ratio (%)	62.55 ± 10.18	68.21 ± 10.50	0.001
1-month mortality (%)	3 (4.11)	11 (14.29)	0.013



*Comparison between severe and mild/moderate patients. Chi-square test was used to compare the rates. Comparison between two groups was analyzed by Student t-test. SIRT6: sirtuin 6; CAP: community acquired pneumonia; PCIS: pediatric critical illness score; CRP: c-reactive protein; PCT: procalcitonin; IL-6: interleukin-6; WBC: white blood cells.

Table 4. Logistic regression for risk factors of 1-month mortality in severe CAP child parents

Variables	Wald	Odds ratio	95% CI	P
Age	5.511	0.686	0.500-0.940	0.019
PCIS	3.159	0.902	0.804-1.011	0.076
SIRT6	0.459	0.932	0.759-1.143	0.498
CRP	4.332	1.028	1.002-1.054	0.038
PCT	0.647	0.994	0.979-1.009	0.421
IL-6	0.060	0.999	0.990-1.008	0.807
WBC	1.289	0.923	0.804-1.060	0.256
Neutrophil ratio	0.237	1.017	0.951-1.086	0.626

SIRT6: sirtuin 6; CAP: community acquired pneumonia; PCIS: pediatric critical illness score; CRP: c-reactive protein; PCT: procalcitonin; IL-6: interleukin-6; WBC: white blood cells; CI: confidence interval.

ICU admission, as well as mortality¹⁴. Even in COVID-19, CRP, PCT, and IL-6 are elevated in serum, however might be lower than CAP patients¹⁵. In our research,

**Figure 2. ROC curve for diagnostic value of SIRT6 for child severe CAP. ROC: receiver operating characteristic; SIRT6: sirtuin 6; CAP: community acquired pneumonia.****Figure 3. K-M curve for 1-mon mortality in SIRT6 high/low severe child CAP parents. SIRT6: sirtuin 6; CAP: community acquired pneumonia.**

we also showed that CRP, PCT, and IL-6 were increased in severe CAP child patients. Besides, we also found that SIRT6 was negatively correlated with these inflammatory factors, suggesting that SIRT6 might influence CAP through regulation of inflammatory response in CAP.

The relationship between SIRT6 and inflammation has been demonstrated in several researches. Chen et al. demonstrated that overexpression of SIRT6 could suppress inflammation, oxidative stress, and cell apoptosis in spinal cord injury¹⁶. In other studies, SIRT6 was found to inhibit TNF- α -induced inflammation in vascular adventitial fibroblasts through ROS and Akt pathways^{17,18}. Besides, hydroxytyrosol acetate was also observed to protect against inflammation of vascular endothelial cells through the activation of SIRT6¹⁹. In a recent study, SIRT6 was found to be down-regulated

in pre-diabetic overweight patients and was associated with increased levels of inflammatory factors²⁰. All these results indicate that SIRT6 is an anti-inflammation factor which is decreased in inflammation and can protect against inflammation-related process. However, up to now, no research focused on role of SIRT6 in CAP, especially in child patients. In our research, we demonstrated for the first time that SIRT6 was decreased in severe CAP patients and lower SIRT6 was associated with increased inflammatory factors, poorer clinical outcomes, and higher 1-month mortality rate.

This study also has some limitations. The sample size is small and the underlying molecular mechanism for SIRT6 in CAP is unclear. All these need more studies to reveal.

Conclusion

This observational study showed that SIRT6 was downregulated in severe CAP child patients, and lower SIRT6 levels were correlated with higher expression of inflammatory factors, severer clinical outcomes, and poor prognosis. This study might provide a novel research target and potential biomarker for CAP in child patients.

Acknowledgments

The authors would like to acknowledge everyone for their helpful contributions on this paper.

Funding

The authors declare no funding.

Conflicts of interest

All authors declare no conflicts of interest.

Ethical disclosures

Protection of human and animal subjects. The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

References

1. Ferreira-Coimbra J, Sarda C, Rello J. Burden of community-acquired pneumonia and unmet clinical needs. *Adv Ther.* 2020;37:1302-18.
2. Katz SE, Williams DJ. Pediatric community-acquired pneumonia in the United States: changing epidemiology, diagnostic and therapeutic challenges, and areas for future research. *Infect Dis Clin North Am.* 2018;32:47-63.
3. Takeuchi N, Naito S, Ohkusu M, Abe K, Shizuno K, Takahashi Y, et al. Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan. *Epidemiol Infect.* 2020;148:e91.
4. Trammer-Stranders GA. Childhood community-acquired pneumonia: a review of etiology and antimicrobial treatment studies. *Paediatr Respir Rev.* 2018;26:41-8.
5. McAllister DA, Liu L, Shi T, Chu Y, Reed C, Burrows J, et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis. *Lancet Glob Health.* 2019;7:e47-57.
6. Liang G, Zheng L. A transfer learning method with deep residual network for pediatric pneumonia diagnosis. *Comput Methods Programs Biomed.* 2020;187:104964.
7. Kuang J, Chen L, Tang Q, Zhang J, Li Y, He J. The role of sirt6 in obesity and diabetes. *Front Physiol.* 2018;9:135.
8. Lerrer B, Gertler AA, Cohen HY. The complex role of SIRT6 in carcinogenesis. *Carcinogenesis.* 2016;37:108-18.
9. D'Onofrio N, Servillo L, Balestrieri ML. SIRT1 and SIRT6 signaling pathways in cardiovascular disease protection. *Antioxid Redox Signal.* 2018;28:711-32.
10. Simon M, Van Meter M, Ablaeva J, Ke Z, Gonzalez RS, Taguchi T, et al. LINE1 derepression in aged wild-type and SIRT6-deficient mice drives inflammation. *Cell Metab.* 2019;29:871-85.
11. Jin XM, Xu X. The society of pediatrics, Chinese medical association-an intensive training programme for developmental and behavioral pediatrics. *Zhonghua Er Ke Za Zhi.* 2013;51:879-80.
12. José R, Williams A, Sulikowski M, Brealey D, Brown J, Chambers R. Regulation of neutrophilic inflammation in lung injury induced by community-acquired pneumonia. *Lancet.* 2015;385:S52.
13. Curbelo J, Bueno SL, Galván-Román JM, Ortega-Gómez M, Rajas O, Fernández-Jiménez G, et al. Inflammation biomarkers in blood as mortality predictors in community-acquired pneumonia admitted patients: importance of comparison with neutrophil count percentage or neutrophil-lymphocyte ratio. *PLoS One.* 2017;12:e0173947.
14. Khan F, Owens MB, Restrepo M, Povoia P, Martin-Loeches I. Tools for outcome prediction in patients with community acquired pneumonia. *Expert Rev Clin Pharmacol.* 2017;10:201-11.
15. Zhou YZ, Teng XB, Han MF, Shi JF, Li CX, Zhang XH, et al. The value of PCT, IL-6, and CRP in the early diagnosis and evaluation of COVID-19. *Eur Rev Med Pharmacol Sci.* 2021;25:1097-100.
16. Zhaohui C, Shuihua W. Protective effects of SIRT6 against inflammation, oxidative stress, and cell apoptosis in spinal cord injury. *Inflammation.* 2020;43:1751-8.
17. He Y, Xiao Y, Yang X, Li Y, Wang B, Yao F, et al. SIRT6 inhibits TNF- α -induced inflammation of vascular adventitial fibroblasts through ROS and Akt signaling pathway. *Exp Cell Res.* 2017;357:88-97.
18. He Y, Yang G, Yao F, Xian Y, Wang G, Chen L, et al. Sitagliptin inhibits vascular inflammation via the SIRT6-dependent signaling pathway. *Int Immunopharmacol.* 2019;75:105805.
19. Yao F, Yang G, Xian Y, Wang G, Zheng Z, Jin Z, et al. The protective effect of hydroxytyrosol acetate against inflammation of vascular endothelial cells partly through the SIRT6-mediated PKM2 signaling pathway. *Food Function.* 2019;10:5789-803.
20. D'Onofrio N, Pieretti G, Ciccirelli F, Gambardella A, Passariello N, Rizzo MR, et al. Abdominal fat SIRT6 expression and its relationship with inflammatory and metabolic pathways in pre-diabetic overweight patients. *Int J Mol Sci.* 2019;20:1153.